Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Noble Life Sciences Partners with BioFactura

Published: Friday, July 27, 2012
Last Updated: Friday, July 27, 2012
Bookmark and Share
Partnership to offer cell line development and preclinical protein production services.

Noble Life Sciences, Inc. has announced a partnership with BioFactura, Inc. (Rockville, MD), a developer and provider of proprietary technologies and services for production of biological.

The collaboration expands Noble’s CRO services to include the development and production of monoclonal antibody and other protein-based drugs.

Through the partnership, Noble becomes the exclusive commercial contract services provider of BioFactura’s technologies and capabilities.

BioFactura’s capabilities enable rapid, scalable, high potency production of protein drug candidates in mammalian and microbial systems, from development of expression vectors and cell lines to growth medium optimization, protein purification, and process scale-up.

BioFactura’s StableFast™ biomanufacturing platform is a unique, patented system for developing stable mammalian NS0 cell lines that can generate over one gram of protein in eight weeks.

“This relationship allows Noble to offer end-to-end preclinical biopharmaceutical development services - from cell line development to protein production, in vitro screening, in vivo efficacy and pharmacodynamics testing and biomarker development” said Alain Cappeluti, Noble Life Sciences President.

“We are looking forward to working with Noble to provide drug developers wider access to our unique capabilities,” said Darryl Sampey, BioFactura’s President and CEO.

Sampey continued, “This partnership creates an excellent synergy between Noble’s experienced scientific drug development team and BioFactura’s protein bioprocessing expertise.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Noble Life Sciences Receives Maryland TEDCO Award
Licenses Vitatex patents for enrichment of invasive circulating tumor cells.
Friday, December 06, 2013
Scientific News
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
Improving Delivery of Poorly Soluble Drugs Using Nanoparticles
A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Nanoparticles Deliver Tumor Suppressors to Damaged Livers
UT Southwestern Medical Center chemists have successfully used synthetic nanoparticles to deliver tumor-suppressing therapies to diseased livers with cancer, an important hurdle scientists have been struggling to conquer.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
A New Type of Anticancer Agent
Success in the development of a ?-tubulin specific inhibitor.
Nanoparticles Proven Effective Against Antibiotic-Resistant “Superbugs”
In the ever-escalating evolutionary battle with drug-resistant bacteria, humans may soon have a leg up thanks to adaptive, light-activated nanotherapy developed by researchers at the University of Colorado Boulder.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!